Microbot Medical to Unveil World's First Fully Disposable Robotic System for Endovascular Procedures Live Demonstration Planned for Monday

Medical to Unveil World's First Fully Disposable Robotic System for Endovascular Procedures

Live Demonstration Planned for Monday, January 13, 2020, in San Francisco

Breakthrough technology features compact design, remote operation capabilities and an integrated "One & Done " tool to democratize endovascular procedures

Mass., Dec. 23, 2019 - Microbot Medical Inc. (NASDAQ: MBOT) today announced the revealing of LIBERTYTM,

the world's first fully disposable robotic system for use in neurovascular, cardiovascular and peripheral vascular procedures.

The LIBERTY robotic system features a unique compact design with the capability to be operated remotely, reduce radiation exposure

and physical strain to the physician, as well as the potential to eliminate the use of multiple consumables through its "One

& Done" capabilities. Microbot is set to publicly display and demonstrate LIBERTY to investors, journalists and healthcare

industry leaders on Monday, January 13, 2020, in San Francisco.

is set to revolutionize the way surgical robotics are being used in endovascular procedures, by eliminating the need for capital

equipment, reducing radiation exposure and aiming to streamline the use of disposables during these complex procedures,"

commented Harel Gadot, Chief Executive Officer, President, and Chairman. "In addition, with LIBERTY's remote operation

as well as its "One & Done" capabilities, we believe it has the potential to be the first system to democratize

endovascular interventional procedures."

Eyal Morag, an ABR certified Interventional Radiologist and Chairman of Radiology and Nuclear Medicine at Assuta Ashdod Medical

Center in Israel, will be performing the live demonstrations highlighting the unique capabilities of LIBERTY.

believe LIBERTY will be welcomed by the interventional community due to its clinical and technical benefits in various subspecialties,

such as neurovascular, cardiovascular and peripheral vascular interventions," commented Dr. Morag. "The system set

up is easy and straightforward, and it offers intuitive remote operation capabilities. These features are designed to reduce

radiation exposure and eliminate physical strain on the physicians. Lastly, I believe it will democratize vascular procedures

by shortening the physician's learning curve"

Unveiling/Demonstration

Event & Webcast Video

attend the LIBERTY unveiling and demonstration event on Monday, January 13, at 7:00 am PT, please contact Michael Polyviou at

732-933-2754 or mpolyviou@evcgroup.com.

of the media should contact Erich Sandoval at 212-867-1762 or erich.sandoval@finnpartners.com.

January 13, at 10:00 am ET

full presentation of the unveiling and demonstration will be available and may be accessed in the Investors' section

of the Company's website at www.microbotmedical.com.

the Company will be hosting One-on-One meetings in San Francisco on Monday, January 13, beginning at 9:00 am PT, through Wednesday,

January 15, at 3:00 pm PT. To schedule a One-on-One meeting and a private demonstration, please contact Michael Polyviou at 732-933-2754

or mpolyviou@evcgroup.com.

Microbot Medical, Inc.

Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies,

focused primarily on both natural and artificial lumens within the human body. Microbot's current proprietary technological

platforms provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).

Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes

for patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical

is available at http://www.microbotmedical.com.

pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential

opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs,

goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities

Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not

limited to statements that contain words such as "will," "believes," "plans," "anticipates,"

"expects" and "estimates") should also be considered to be forward-looking statements. Forward-looking

statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization

of potential products, including LIBERTY, the outcome of its studies to evaluate the SCS and other existing and future technologies,

uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, need and ability

to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results

anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect

the businesses of Microbot Medical Inc. particularly those mentioned in the cautionary statements found in Microbot Medical Inc.'s

filings with the Securities and Exchange Commission. Microbot Medical disclaims any intent or obligation to update these forward-looking